Table 7 Pim kinase inhibitors used in preclinical and clinical (bold) trials for MPNs
From: Targeting Pim kinases in hematological cancers: molecular and clinical review
| Â | Pim Inhibitor | Target | Type | Clinical Trials | Â |
|---|---|---|---|---|---|
MPNs | AZD1208 | pan-Pim | Single | Yes | – |
AZD1208 + Ruxolitinib | pan-Pim + JAK | Dual-therapy | Preclinical | – | |
SGI-1776 | Pim1/Pim2 | Single | Yes | – | |
INCB053914 + Ruxolitinib | pan-Pim + JAK | Dual-therapy | Preclinical | – | |
PIM447 | pan-Pim | Single | MF | NCT02370706 | |
PIM447 + Ruxolitinib + LEE011 | pan-Pim + JAK + CDK4/6 | Triple-therapy | Preclinical | – | |
TP-3654 | pan-Pim | Single | MF | NCT04176198 | |
TP-3654 + Ruxolitinib | pan-Pim + JAK | Dual-therapy | Preclinical | – | |
Pim inhibitor (PIM447) + SAR302503 (TG101348) | pan-Pim + JAK | Dual-therapy | Preclinical | – | |
Uzansertib | pan-Pim | Single | MF | NCT02587598 | |
CML | Smi-4a | Pim1 | Single | Preclinical | – |
AZD1208 | pan-Pim | Single | Yes | – | |
AZD1208 + imatinib mesylate | pan-Pim + TKI | Dual-therapy | No | – | |
SGI-1776 | Pim1 |  | Yes | – | |
SGI-1776 + imatinib mesylate | pan-Pim + TKI | Dual-therapy | No | – |